header image

intellectual property (IP)

MicroDose has a dominant and broad patent estate of both issued and
pending patents supporting all of its drug delivery platforms

MicroDose considers strong and broad Intellectual Property (IP) protection to be a key strategy for sustaining competitive advantage. MicroDose performs its own core research and development and aims to secure multi-layered registered protection for its technologies, products and processes. All of MicroDose’s drug delivery platforms are supported by issued US and international patents as well as pending patent applications; all IP is wholly owned by the Company. MicroDose, in turn, makes its intellectual property available to partners under appropriate licensing agreements.

MicroDose’s intellectual property portfolio updated January, 2012

Patent Portfolio by Technology

Product U.S. Patents Issued U.S. Patent Applications Pending Intl Patents Issued Intl Patents Pending PCT Applications
Pulmonary
11
15
113
124
4
Oral Dose
3
4
5
17
1
Packaging
4
2
30
5
Transdermal
2
0 0 0 0
Compounds
1
11 0 18 1
Total
21
32
148
164
6
Trademarks
3
3
6
7
n/a